Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial
Identifieur interne : 006B58 ( Main/Exploration ); précédent : 006B57; suivant : 006B59Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial
Auteurs : Henry Krum [Australie] ; Dirk J. Van Veldhuisen [Pays-Bas] ; Christian Funck-Brentano [France] ; Emilio Vanoli [Italie] ; Bernard Silke [Irlande (pays)] ; Erland Erdmann [Allemagne] ; Ferenc Follath [Suisse] ; Piotr Ponikowski [Pologne] ; Michael Goulder [Royaume-Uni] ; Wilfried Meyer [Allemagne] ; Philippe Lechat [France] ; Ronnie Willenheimer [Suède]Source :
- Cardiovascular therapeutics : (Print) [ 1755-5914 ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Médicament.
English descriptors
- KwdEn :
Abstract
Background: Mode of death in chronic heart failure (CHF) may be of relevance to choice of therapy for this condition. Sudden death is particularly common in patients with early and/or mild/moderate CHF. β-Blockade may provide better protection against sudden death than ACE inhibition (ACEI) in this setting. Methods: We randomized 1010 patients with mild or moderate, stable CHF and left ventricular ejection fraction ≤35%, without ACEI, β-blocker or angiotensin-receptor-blocker therapy, to either bisoprolol (n = 505) or enalapril (n = 505) for 6 months, followed by their combination for 6-24 months. The two strategies were blindly compared regarding adjudicated mode of death, including sudden death and progressive pump failure death. Results: During the monotherapy phase, 8 of 23 deaths in the bisoprolol-first group were sudden, compared to 16 of 32 in the enalapril-first group: hazard ratio (HR) for sudden death 0.50; 95% confidence interval (CI) 0.21-1.16; P = 0.107. At 1 year, 16 of 42 versus 29 of 60 deaths were sudden: HR 0.54; 95% CI 0.29-1.00; P = 0.049. At study end, 29 of 65 versus 34 of 73 deaths were sudden: HR 0.84; 95% CI 0.51-1.38; P = 0.487. Comparable figures for pump failure death were: monotherapy, 7 of 23 deaths versus 2 of 32: HR 3.43; 95% CI 0.71-16.53; P = 0.124, at 1 year, 13 of 42 versus 5 of 60: HR 2.57; 95% CI 0.92-7.20; P = 0.073, at study end, 17 of 65 versus 7 of 73: HR 2.39; 95% CI 0.99-5.75; P = 0.053. There were no significant between-group differences in any other fatal events. Conclusion: Initiating therapy with bisoprolol compared to enalapril decreased the risk of sudden death during the first year in this mild systolic CHF cohort. This was somewhat offset by an increase in pump failure deaths in the bisoprolol-first cohort.
Affiliations:
- Allemagne, Australie, France, Irlande (pays), Italie, Pays-Bas, Pologne, Royaume-Uni, Suisse, Suède
- District de Darmstadt, Hesse (Land), Victoria (État), Île-de-France
- Darmstadt, Melbourne, Paris
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001E80
- to stream PascalFrancis, to step Curation: 004057
- to stream PascalFrancis, to step Checkpoint: 001B55
- to stream Main, to step Merge: 007006
- to stream Main, to step Curation: 006B58
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial</title><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Epidemiology and Preventive Medicine and Medicine, Monash University, Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Thoraxcenter, Department of Cardiology, University Hospital Groningen</s1><s3>NLD</s3><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Thoraxcenter, Department of Cardiology, University Hospital Groningen</wicri:noRegion></affiliation></author><author><name sortKey="Funck Brentano, Christian" sort="Funck Brentano, Christian" uniqKey="Funck Brentano C" first="Christian" last="Funck-Brentano">Christian Funck-Brentano</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>UPMC - AP-HP - INSERM CIC9304, Department of Pharmacology, Pitié-Salpêtrière Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Vanoli, Emilio" sort="Vanoli, Emilio" uniqKey="Vanoli E" first="Emilio" last="Vanoli">Emilio Vanoli</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Cardiology, University of Pavia and Policlinico di Monza</s1><s3>ITA</s3><sZ>4 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Department of Cardiology, University of Pavia and Policlinico di Monza</wicri:noRegion></affiliation></author><author><name sortKey="Silke, Bernard" sort="Silke, Bernard" uniqKey="Silke B" first="Bernard" last="Silke">Bernard Silke</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pharmacology & Therapeutics, Trinity Centre, St James' Hospital</s1><s2>Dublin</s2><s3>IRL</s3><sZ>5 aut.</sZ></inist:fA14><country>Irlande (pays)</country><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Erdmann, Erland" sort="Erdmann, Erland" uniqKey="Erdmann E" first="Erland" last="Erdmann">Erland Erdmann</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Medizinische Klinik III, University of Cologne</s1><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>University of Cologne</wicri:noRegion><wicri:noRegion>Medizinische Klinik III, University of Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Follath, Ferenc" sort="Follath, Ferenc" uniqKey="Follath F" first="Ferenc" last="Follath">Ferenc Follath</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Medicine A, University Hospital Zürich</s1><s3>CHE</s3><sZ>7 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Medicine A, University Hospital Zürich</wicri:noRegion></affiliation></author><author><name sortKey="Ponikowski, Piotr" sort="Ponikowski, Piotr" uniqKey="Ponikowski P" first="Piotr" last="Ponikowski">Piotr Ponikowski</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Heart Diseases, Medical University</s1><s2>Wroclaw</s2><s3>POL</s3><sZ>8 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Wroclaw</wicri:noRegion></affiliation></author><author><name sortKey="Goulder, Michael" sort="Goulder, Michael" uniqKey="Goulder M" first="Michael" last="Goulder">Michael Goulder</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Worldwide Clinical Trials</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Worldwide Clinical Trials</wicri:noRegion></affiliation></author><author><name sortKey="Meyer, Wilfried" sort="Meyer, Wilfried" uniqKey="Meyer W" first="Wilfried" last="Meyer">Wilfried Meyer</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Merck KGaA</s1><s2>Darmstadt</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Darmstadt</settlement></placeName></affiliation></author><author><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Service de Pharmacologie, Hopital Pitié-Salpetriere</s1><s2>Paris</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Willenheimer, Ronnie" sort="Willenheimer, Ronnie" uniqKey="Willenheimer R" first="Ronnie" last="Willenheimer">Ronnie Willenheimer</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Lund University and Heart Health Group</s1><s2>Malmö</s2><s3>SWE</s3><sZ>12 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>Lund University and Heart Health Group</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0167396</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0167396 INIST</idno><idno type="RBID">Pascal:11-0167396</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E80</idno><idno type="wicri:Area/PascalFrancis/Curation">004057</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B55</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001B55</idno><idno type="wicri:doubleKey">1755-5914:2011:Krum H:effect:on:mode</idno><idno type="wicri:Area/Main/Merge">007006</idno><idno type="wicri:Area/Main/Curation">006B58</idno><idno type="wicri:Area/Main/Exploration">006B58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial</title><author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Departments of Epidemiology and Preventive Medicine and Medicine, Monash University, Alfred Hospital</s1><s2>Melbourne</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Thoraxcenter, Department of Cardiology, University Hospital Groningen</s1><s3>NLD</s3><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>Thoraxcenter, Department of Cardiology, University Hospital Groningen</wicri:noRegion></affiliation></author><author><name sortKey="Funck Brentano, Christian" sort="Funck Brentano, Christian" uniqKey="Funck Brentano C" first="Christian" last="Funck-Brentano">Christian Funck-Brentano</name><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>UPMC - AP-HP - INSERM CIC9304, Department of Pharmacology, Pitié-Salpêtrière Hospital</s1><s2>Paris</s2><s3>FRA</s3><sZ>3 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Vanoli, Emilio" sort="Vanoli, Emilio" uniqKey="Vanoli E" first="Emilio" last="Vanoli">Emilio Vanoli</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Cardiology, University of Pavia and Policlinico di Monza</s1><s3>ITA</s3><sZ>4 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Department of Cardiology, University of Pavia and Policlinico di Monza</wicri:noRegion></affiliation></author><author><name sortKey="Silke, Bernard" sort="Silke, Bernard" uniqKey="Silke B" first="Bernard" last="Silke">Bernard Silke</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Pharmacology & Therapeutics, Trinity Centre, St James' Hospital</s1><s2>Dublin</s2><s3>IRL</s3><sZ>5 aut.</sZ></inist:fA14><country>Irlande (pays)</country><wicri:noRegion>Dublin</wicri:noRegion></affiliation></author><author><name sortKey="Erdmann, Erland" sort="Erdmann, Erland" uniqKey="Erdmann E" first="Erland" last="Erdmann">Erland Erdmann</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Medizinische Klinik III, University of Cologne</s1><s3>DEU</s3><sZ>6 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>University of Cologne</wicri:noRegion><wicri:noRegion>Medizinische Klinik III, University of Cologne</wicri:noRegion></affiliation></author><author><name sortKey="Follath, Ferenc" sort="Follath, Ferenc" uniqKey="Follath F" first="Ferenc" last="Follath">Ferenc Follath</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Medicine A, University Hospital Zürich</s1><s3>CHE</s3><sZ>7 aut.</sZ></inist:fA14><country>Suisse</country><wicri:noRegion>Medicine A, University Hospital Zürich</wicri:noRegion></affiliation></author><author><name sortKey="Ponikowski, Piotr" sort="Ponikowski, Piotr" uniqKey="Ponikowski P" first="Piotr" last="Ponikowski">Piotr Ponikowski</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Department of Heart Diseases, Medical University</s1><s2>Wroclaw</s2><s3>POL</s3><sZ>8 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Wroclaw</wicri:noRegion></affiliation></author><author><name sortKey="Goulder, Michael" sort="Goulder, Michael" uniqKey="Goulder M" first="Michael" last="Goulder">Michael Goulder</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Worldwide Clinical Trials</s1><s2>Nottingham</s2><s3>GBR</s3><sZ>9 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Worldwide Clinical Trials</wicri:noRegion></affiliation></author><author><name sortKey="Meyer, Wilfried" sort="Meyer, Wilfried" uniqKey="Meyer W" first="Wilfried" last="Meyer">Wilfried Meyer</name><affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Merck KGaA</s1><s2>Darmstadt</s2><s3>DEU</s3><sZ>10 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Darmstadt</region><settlement type="city">Darmstadt</settlement></placeName></affiliation></author><author><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Service de Pharmacologie, Hopital Pitié-Salpetriere</s1><s2>Paris</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Willenheimer, Ronnie" sort="Willenheimer, Ronnie" uniqKey="Willenheimer R" first="Ronnie" last="Willenheimer">Ronnie Willenheimer</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Lund University and Heart Health Group</s1><s2>Malmö</s2><s3>SWE</s3><sZ>12 aut.</sZ></inist:fA14><country>Suède</country><wicri:noRegion>Lund University and Heart Health Group</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Cardiovascular therapeutics : (Print)</title><title level="j" type="abbreviated">Cardiovasc. ther. : (Print)</title><idno type="ISSN">1755-5914</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Cardiovascular therapeutics : (Print)</title><title level="j" type="abbreviated">Cardiovasc. ther. : (Print)</title><idno type="ISSN">1755-5914</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>ACE inhibitor</term><term>Antihypertensive agent</term><term>Beta blocking agent</term><term>Bisoprolol</term><term>Cardiocirculatory arrest</term><term>Drug</term><term>Enalapril</term><term>Heart failure</term><term>Randomization</term><term>Result</term><term>Sudden death</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Mort subite</term><term>Insuffisance cardiaque</term><term>Traitement</term><term>Bisoprolol</term><term>Enalapril</term><term>Résultat</term><term>Randomisation</term><term>Bloquant β-adrénergique</term><term>Inhibiteur angiotensin converting enzyme</term><term>Médicament</term><term>Arrêt cardiocirculatoire</term><term>Antihypertenseur</term><term>Arrêt cardiorespiratoire</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Mode of death in chronic heart failure (CHF) may be of relevance to choice of therapy for this condition. Sudden death is particularly common in patients with early and/or mild/moderate CHF. β-Blockade may provide better protection against sudden death than ACE inhibition (ACEI) in this setting. Methods: We randomized 1010 patients with mild or moderate, stable CHF and left ventricular ejection fraction ≤35%, without ACEI, β-blocker or angiotensin-receptor-blocker therapy, to either bisoprolol (n = 505) or enalapril (n = 505) for 6 months, followed by their combination for 6-24 months. The two strategies were blindly compared regarding adjudicated mode of death, including sudden death and progressive pump failure death. Results: During the monotherapy phase, 8 of 23 deaths in the bisoprolol-first group were sudden, compared to 16 of 32 in the enalapril-first group: hazard ratio (HR) for sudden death 0.50; 95% confidence interval (CI) 0.21-1.16; P = 0.107. At 1 year, 16 of 42 versus 29 of 60 deaths were sudden: HR 0.54; 95% CI 0.29-1.00; P = 0.049. At study end, 29 of 65 versus 34 of 73 deaths were sudden: HR 0.84; 95% CI 0.51-1.38; P = 0.487. Comparable figures for pump failure death were: monotherapy, 7 of 23 deaths versus 2 of 32: HR 3.43; 95% CI 0.71-16.53; P = 0.124, at 1 year, 13 of 42 versus 5 of 60: HR 2.57; 95% CI 0.92-7.20; P = 0.073, at study end, 17 of 65 versus 7 of 73: HR 2.39; 95% CI 0.99-5.75; P = 0.053. There were no significant between-group differences in any other fatal events. Conclusion: Initiating therapy with bisoprolol compared to enalapril decreased the risk of sudden death during the first year in this mild systolic CHF cohort. This was somewhat offset by an increase in pump failure deaths in the bisoprolol-first cohort.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>France</li><li>Irlande (pays)</li><li>Italie</li><li>Pays-Bas</li><li>Pologne</li><li>Royaume-Uni</li><li>Suisse</li><li>Suède</li></country><region><li>District de Darmstadt</li><li>Hesse (Land)</li><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Darmstadt</li><li>Melbourne</li><li>Paris</li></settlement></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name></region></country><country name="Pays-Bas"><noRegion><name sortKey="Van Veldhuisen, Dirk J" sort="Van Veldhuisen, Dirk J" uniqKey="Van Veldhuisen D" first="Dirk J." last="Van Veldhuisen">Dirk J. Van Veldhuisen</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Funck Brentano, Christian" sort="Funck Brentano, Christian" uniqKey="Funck Brentano C" first="Christian" last="Funck-Brentano">Christian Funck-Brentano</name></region><name sortKey="Lechat, Philippe" sort="Lechat, Philippe" uniqKey="Lechat P" first="Philippe" last="Lechat">Philippe Lechat</name></country><country name="Italie"><noRegion><name sortKey="Vanoli, Emilio" sort="Vanoli, Emilio" uniqKey="Vanoli E" first="Emilio" last="Vanoli">Emilio Vanoli</name></noRegion></country><country name="Irlande (pays)"><noRegion><name sortKey="Silke, Bernard" sort="Silke, Bernard" uniqKey="Silke B" first="Bernard" last="Silke">Bernard Silke</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Erdmann, Erland" sort="Erdmann, Erland" uniqKey="Erdmann E" first="Erland" last="Erdmann">Erland Erdmann</name></noRegion><name sortKey="Meyer, Wilfried" sort="Meyer, Wilfried" uniqKey="Meyer W" first="Wilfried" last="Meyer">Wilfried Meyer</name></country><country name="Suisse"><noRegion><name sortKey="Follath, Ferenc" sort="Follath, Ferenc" uniqKey="Follath F" first="Ferenc" last="Follath">Ferenc Follath</name></noRegion></country><country name="Pologne"><noRegion><name sortKey="Ponikowski, Piotr" sort="Ponikowski, Piotr" uniqKey="Ponikowski P" first="Piotr" last="Ponikowski">Piotr Ponikowski</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Goulder, Michael" sort="Goulder, Michael" uniqKey="Goulder M" first="Michael" last="Goulder">Michael Goulder</name></noRegion></country><country name="Suède"><noRegion><name sortKey="Willenheimer, Ronnie" sort="Willenheimer, Ronnie" uniqKey="Willenheimer R" first="Ronnie" last="Willenheimer">Ronnie Willenheimer</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006B58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006B58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0167396
|texte= Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial
}}
| This area was generated with Dilib version V0.6.33. |  |